Clinical Trial Update: Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial updates show Circadin (melatonin) demonstrating efficacy and safety for Non-24-hour sleep-wake disorder in totally blind subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-24-hour Sleep-wake Disorder

Drugs mentioned

• Circadin (melatonin)

Snippet

Sponsor: Neurim Pharmaceuticals Ltd. | Conditions: Non-24 Hour Sleep-Wake Disorder, Blindness | Phase 2 | Status: COMPLETED